219 related articles for article (PubMed ID: 37341056)
1. Expression of cancer-testis antigens in the immune microenvironment of non-small cell lung cancer.
Hikmet F; Rassy M; Backman M; Méar L; Mattsson JSM; Djureinovic D; Botling J; Brunnström H; Micke P; Lindskog C
Mol Oncol; 2023 Dec; 17(12):2603-2617. PubMed ID: 37341056
[TBL] [Abstract][Full Text] [Related]
2. Profiling cancer testis antigens in non-small-cell lung cancer.
Djureinovic D; Hallström BM; Horie M; Mattsson JSM; La Fleur L; Fagerberg L; Brunnström H; Lindskog C; Madjar K; Rahnenführer J; Ekman S; Ståhle E; Koyi H; Brandén E; Edlund K; Hengstler JG; Lambe M; Saito A; Botling J; Pontén F; Uhlén M; Micke P
JCI Insight; 2016 Jul; 1(10):e86837. PubMed ID: 27699219
[TBL] [Abstract][Full Text] [Related]
3. Predictive and prognostic effect of CD133 and cancer-testis antigens in stage Ib-IIIA non-small cell lung cancer.
Su C; Xu Y; Li X; Ren S; Zhao C; Hou L; Ye Z; Zhou C
Int J Clin Exp Pathol; 2015; 8(5):5509-18. PubMed ID: 26191258
[TBL] [Abstract][Full Text] [Related]
4. Cancer/Testis Antigens: Expression, Regulation, Tumor Invasion, and Use in Immunotherapy of Cancers.
Salmaninejad A; Zamani MR; Pourvahedi M; Golchehre Z; Hosseini Bereshneh A; Rezaei N
Immunol Invest; 2016 Oct; 45(7):619-40. PubMed ID: 27603913
[TBL] [Abstract][Full Text] [Related]
5. Detection of autoantibodies against cancer-testis antigens in non-small cell lung cancer.
Djureinovic D; Dodig-Crnković T; Hellström C; Holgersson G; Bergqvist M; Mattsson JSM; Pontén F; Ståhle E; Schwenk JM; Micke P
Lung Cancer; 2018 Nov; 125():157-163. PubMed ID: 30429015
[TBL] [Abstract][Full Text] [Related]
6. Cancer testis antigen burden (CTAB): a novel biomarker of tumor-associated antigens in lung cancer.
Seager RJ; Senosain MF; Van Roey E; Gao S; DePietro P; Nesline MK; Dash DP; Zhang S; Ko H; Hastings SB; Strickland KC; Previs RA; Jensen TJ; Eisenberg M; Caveney BJ; Severson EA; Ramkissoon S; Conroy JM; Pabla S
J Transl Med; 2024 Feb; 22(1):141. PubMed ID: 38326843
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic cancer/testis antigens are a hallmarker of cancer and a sensible target for cancer immunotherapy.
Yang P; Meng M; Zhou Q
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188558. PubMed ID: 33933558
[TBL] [Abstract][Full Text] [Related]
8. Expression of cancer-testis antigens MAGE-A3/6 and NY-ESO-1 in non-small-cell lung carcinomas and their relationship with immune cell infiltration.
Kim SH; Lee S; Lee CH; Lee MK; Kim YD; Shin DH; Choi KU; Kim JY; Park DY; Sol MY
Lung; 2009; 187(6):401-11. PubMed ID: 19795170
[TBL] [Abstract][Full Text] [Related]
9. Novel antigens in non-small cell lung cancer: SP17, AKAP4, and PTTG1 are potential immunotherapeutic targets.
Mirandola L; Figueroa JA; Phan TT; Grizzi F; Kim M; Rahman RL; Jenkins MR; Cobos E; Jumper C; Alalawi R; Chiriva-Internati M
Oncotarget; 2015 Feb; 6(5):2812-26. PubMed ID: 25739119
[TBL] [Abstract][Full Text] [Related]
10. The role of Cancer-Testis antigens as predictive and prognostic markers in non-small cell lung cancer.
John T; Starmans MH; Chen YT; Russell PA; Barnett SA; White SC; Mitchell PL; Walkiewicz M; Azad A; Lambin P; Tsao MS; Deb S; Altorki N; Wright G; Knight S; Boutros PC; Cebon JS
PLoS One; 2013; 8(7):e67876. PubMed ID: 23935846
[TBL] [Abstract][Full Text] [Related]
11. Analysis of GAGE, NY-ESO-1 and SP17 cancer/testis antigen expression in early stage non-small cell lung carcinoma.
Gjerstorff MF; Pøhl M; Olsen KE; Ditzel HJ
BMC Cancer; 2013 Oct; 13():466. PubMed ID: 24103781
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of cancer testis antigen (CT10, PRAME) and MHC I expression in high-grade urothelial carcinoma of the bladder.
Hodgson A; Jungbluth AA; Katabi N; Xu B; Downes MR
Virchows Arch; 2020 Apr; 476(4):535-542. PubMed ID: 31485721
[TBL] [Abstract][Full Text] [Related]
13. Reverse Vaccinology Approach in Constructing a Multi-Epitope Vaccine Against Cancer-Testis Antigens Expressed in Non-Small Cell Lung Cancer.
Herrera LRM
Asian Pac J Cancer Prev; 2021 May; 22(5):1495-1506. PubMed ID: 34048178
[TBL] [Abstract][Full Text] [Related]
14. Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1.
Iura K; Maekawa A; Kohashi K; Ishii T; Bekki H; Otsuka H; Yamada Y; Yamamoto H; Harimaya K; Iwamoto Y; Oda Y
Hum Pathol; 2017 Mar; 61():130-139. PubMed ID: 27993576
[TBL] [Abstract][Full Text] [Related]
15. Cancer/testis antigens: from serology to mRNA cancer vaccine.
Fan C; Qu H; Wang X; Sobhani N; Wang L; Liu S; Xiong W; Zeng Z; Li Y
Semin Cancer Biol; 2021 Nov; 76():218-231. PubMed ID: 33910064
[TBL] [Abstract][Full Text] [Related]
16. Cancer-testis antigens: Unique cancer stem cell biomarkers and targets for cancer therapy.
Gordeeva O
Semin Cancer Biol; 2018 Dec; 53():75-89. PubMed ID: 30171980
[TBL] [Abstract][Full Text] [Related]
17. The prevalence of expression of MAGE-A3 and PRAME tumor antigens in East and South East Asian non-small cell lung cancer patients.
Thongprasert S; Yang PC; Lee JS; Soo R; Gruselle O; Myo A; Louahed J; Lehmann FF; Brichard VG; Coche T
Lung Cancer; 2016 Nov; 101():137-144. PubMed ID: 27794402
[TBL] [Abstract][Full Text] [Related]
18. The potential immune-eliciting cancer testis antigens in colorectal cancer.
Chi Soh JE; Abu N; Jamal R
Immunotherapy; 2018 Sep; 10(12):1093-1104. PubMed ID: 30185136
[TBL] [Abstract][Full Text] [Related]
19. Cancer-testis antigens: promising targets for antigen directed antineoplastic immunotherapy.
Bodey B
Expert Opin Biol Ther; 2002 Aug; 2(6):577-84. PubMed ID: 12171503
[TBL] [Abstract][Full Text] [Related]
20. MAGEA4 induces growth in normal oral keratinocytes by inhibiting growth arrest and apoptosis.
Bhan S; Chuang A; Negi SS; Glazer CA; Califano JA
Oncol Rep; 2012 Oct; 28(4):1498-502. PubMed ID: 22842486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
